{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:28:44Z","timestamp":1787239724296,"version":"build-2736575974"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.peptides.2014.10.005","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T02:20:44Z","timestamp":1413771644000},"page":"189-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"special_numbering":"C","title":["The role of renin-angiotensin system modulation on treatment and prevention of liver diseases"],"prefix":"10.1016","volume":"62","author":[{"given":"Simone Moreira de","family":"Mac\u00eado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talita","family":"Antunes Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John David","family":"Feltenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio Henrique Sousa","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2014.10.005_bib0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2004.09.012","article-title":"The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies","volume":"42","author":"Adams","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0010","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1113\/expphysiol.2007.040345","article-title":"Genetically altered animal models for Mas and angiotensin-(1-7)","volume":"93","author":"Alenina","year":"2008","journal-title":"Exp Physiol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.peptides.2014.10.005_bib0020","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.2337\/db10-1205","article-title":"ACE2 and diabetes: ACE of ACEs?","volume":"59","author":"Batlle","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2014.10.005_bib0025","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.peptides.2014.10.005_bib0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.peptides.2012.08.002","article-title":"Decreased hepatic gluconeogenesis in transgenic rats with increased circulating angiotensin-(1-7)","volume":"37","author":"Bilman","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2014.10.005_bib0035","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mce.2014.05.024","article-title":"The ACE2\/Ang-(1-7)\/Mas axis can inhibit hepatic insulin resistance","volume":"393","author":"Cao","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2007.09.013","article-title":"Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells","volume":"198","author":"Cianchetti","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.peptides.2014.10.005_bib0050","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1572-0241.2003.07486.x","article-title":"The prevalence and etiology of elevated aminotransferase levels in the United States","volume":"98","author":"Clark","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0055","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1478-3231.2009.01973.x","article-title":"The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C","volume":"29","author":"Corey","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.peptides.2014.10.005_bib0060","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.peptides.2014.10.005_bib0065","doi-asserted-by":"crossref","first-page":"R745","DOI":"10.1016\/S0960-9822(02)01255-1","article-title":"Just the beginning: novel functions for angiotensin-converting enzymes","volume":"12","author":"Eriksson","year":"2002","journal-title":"Curr Biol"},{"issue":"Aug (2)","key":"10.1016\/j.peptides.2014.10.005_bib0070","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/HYPERTENSIONAHA.111.00919","article-title":"Oral formulation of angiotensin-(1-7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice","volume":"62","author":"Feltenberger","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.peptides.2014.10.005_bib0075","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/01.HYP.0000196268.08909.fb","article-title":"Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation","volume":"47","author":"Ferrario","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.peptides.2014.10.005_bib0080","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1007\/s00018-004-4243-4","article-title":"Novel angiotensin peptides","volume":"61","author":"Ferrario","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.peptides.2014.10.005_bib0085","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1053\/jhep.2000.20243","article-title":"Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference","volume":"32","author":"Friedman","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.peptides.2014.10.005_bib0090","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1161\/HYPERTENSIONAHA.113.03025","article-title":"Angiotensin-(1-7) recruits muscle microvasculature and enhances insulin's metabolic action via mas receptor","volume":"63","author":"Fu","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.peptides.2014.10.005_bib0095","doi-asserted-by":"crossref","first-page":"12719","DOI":"10.1073\/pnas.96.22.12719","article-title":"In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis","volume":"96","author":"George","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.peptides.2014.10.005_bib0100","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/01.RES.74.6.1141","article-title":"Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells","volume":"74","author":"Griendling","year":"1994","journal-title":"Circ Res"},{"key":"10.1016\/j.peptides.2014.10.005_bib0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.peptides.2012.05.024","article-title":"Exercise induces renin-angiotensin system unbalance and high collagen expression in the heart of Mas-deficient mice","volume":"38","author":"Guimaraes","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2014.10.005_bib0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1755-1536-3-21","article-title":"Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis","volume":"3","author":"Guo","year":"2010","journal-title":"Fibrog Tissue Repair"},{"key":"10.1016\/j.peptides.2014.10.005_bib0115","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejphar.2009.04.042","article-title":"Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes?","volume":"614","author":"Halici","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0120","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","article-title":"Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease","volume":"57","author":"Harrison","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.peptides.2014.10.005_bib0125","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jhep.2007.03.008","article-title":"Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis","volume":"47","author":"Herath","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0130","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1161\/01.CIR.95.6.1532","article-title":"Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis","volume":"95","author":"Hernandez-Presa","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.peptides.2014.10.005_bib0135","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/hep.21638","article-title":"Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis","volume":"45","author":"Hirose","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.peptides.2014.10.005_bib0140","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1440-1681.2009.05302.x","article-title":"Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors","volume":"37","author":"Huang","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0145","first-page":"717","article-title":"Expression of angiotensin-converting enzyme 2 in CCL4-induced rat liver fibrosis","volume":"23","author":"Huang","year":"2009","journal-title":"Int J Mol Med"},{"issue":"8","key":"10.1016\/j.peptides.2014.10.005_bib0150","doi-asserted-by":"crossref","first-page":"e73492","DOI":"10.1371\/journal.pone.0073492","article-title":"Bevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cells","volume":"8","author":"Huang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2014.10.005_bib0155","doi-asserted-by":"crossref","DOI":"10.2174\/1573402110666140812122349","article-title":"Role of renin-angiotensin-aldosterone system in metabolic syndrome and obesity-related hypertension","author":"Kamide","year":"2014","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.peptides.2014.10.005_bib0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0006-291X(03)01357-3","article-title":"AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4)","volume":"308","author":"Kanno","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.peptides.2014.10.005_bib0165","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cardiores.2006.09.006","article-title":"ACE2 of the heart: from angiotensin I to angiotensin (1-7)","volume":"73","author":"Keidar","year":"2007","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.peptides.2014.10.005_bib0170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2010.06.003","article-title":"Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters","volume":"128","author":"Kuba","year":"2010","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.peptides.2014.10.005_bib0175","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/00004872-200412000-00003","article-title":"Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system","volume":"22","author":"Kurtz","year":"2004","journal-title":"J Hypertens"},{"key":"10.1016\/j.peptides.2014.10.005_bib0180","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/ki.2008.313","article-title":"Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue","volume":"74","author":"Lee","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.peptides.2014.10.005_bib0185","doi-asserted-by":"crossref","first-page":"160726","DOI":"10.1155\/2012\/160726","article-title":"Salvianolic acid B attenuates rat hepatic fibrosis via downregulating angiotensin II signaling","volume":"2012","author":"Li","year":"2012","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.peptides.2014.10.005_bib0190","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00029330-200801020-00013","article-title":"Effect of angiotensin II and angiotensin II type 1 receptor antagonist on the proliferation, contraction and collagen synthesis in rat hepatic stellate cells","volume":"121","author":"Liu","year":"2008","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.peptides.2014.10.005_bib0195","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/CS20080647","article-title":"Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat","volume":"117","author":"Lubel","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.peptides.2014.10.005_bib0200","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1053\/j.gastro.2008.03.002","article-title":"Cellular and molecular mechanisms of liver injury","volume":"134","author":"Malhi","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.peptides.2014.10.005_bib0205","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1172\/JCI116778","article-title":"Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells","volume":"92","author":"Marui","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.peptides.2014.10.005_bib0210","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s10620-012-2499-3","article-title":"Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4(\u2212\/\u2212) mouse model","volume":"58","author":"Mende","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.peptides.2014.10.005_bib0215","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1016\/j.bmc.2010.10.043","article-title":"Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists\u2014a perspective","volume":"18","author":"Naik","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.peptides.2014.10.005_bib0225","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/hepr.12008","article-title":"Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis","volume":"43","author":"Noguchi","year":"2013","journal-title":"Hepatol Res"},{"key":"10.1016\/j.peptides.2014.10.005_bib0230","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1053\/jhep.2003.50182","article-title":"Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells","volume":"37","author":"Paik","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.peptides.2014.10.005_bib0235","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1053\/gast.2002.36561","article-title":"Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver","volume":"123","author":"Paizis","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.peptides.2014.10.005_bib0240","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(01)00146-5","article-title":"Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis","volume":"35","author":"Paizis","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0245","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1136\/gut.2004.062398","article-title":"Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2","volume":"54","author":"Paizis","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.peptides.2014.10.005_bib0250","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cld.2012.03.005","article-title":"Nonalcoholic fatty liver disease","volume":"16","author":"Paredes","year":"2012","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.peptides.2014.10.005_bib0255","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.3748\/wjg.15.2579","article-title":"Renin-angiotensin system in the pathogenesis of liver fibrosis","volume":"15","author":"Pereira","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0260","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2006.10.018","article-title":"The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7)","volume":"46","author":"Pereira","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0265","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1161\/01.CIR.0000141736.76561.78","article-title":"Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome","volume":"110","author":"Prasad","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.peptides.2014.10.005_bib0270","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejphar.2012.04.028","article-title":"Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes","volume":"685","author":"Qiang","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0275","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/FJC.0b013e3180986219","article-title":"ACE2: a new target for cardiovascular disease therapeutics","volume":"50","author":"Raizada","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0280","first-page":"978790","article-title":"Effects of angiotensin converting enzyme inhibitors on liver fibrosis in HIV and hepatitis C coinfection","volume":"2012","author":"Reese","year":"2012","journal-title":"AIDS Res Treat"},{"key":"10.1016\/j.peptides.2014.10.005_bib0285","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1097\/00002030-200308150-00009","article-title":"Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)","volume":"17","author":"Rosenthal","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.peptides.2014.10.005_bib0290","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1113\/expphysiol.2008.042002","article-title":"Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis","volume":"93","author":"Santos","year":"2008","journal-title":"Exp Physiol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0295","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.peptides.2014.10.005_bib0300","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0361-9230(94)90104-X","article-title":"Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors","volume":"35","author":"Santos","year":"1994","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.peptides.2014.10.005_bib0305","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11938-005-0029-5","article-title":"Management of chronic hepatitis C virus in patients with HIV","volume":"8","author":"Santos","year":"2005","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0310","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.peptides.2013.05.010","article-title":"Oral Angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin\/TLR4\/MAPK\/NF-kappaB in rats fed with high-fat diet","volume":"46","author":"Santos","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2014.10.005_bib0315","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/ATVBAHA.109.200493","article-title":"Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7)","volume":"30","author":"Santos","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0320","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/15748847112079990050","article-title":"The therapeutic role of Renin-Angiotensin System blockers in obesity-related renal disorders","volume":"9","author":"Santos","year":"2014","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0325","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2337\/db07-0953","article-title":"Mas deficiency in FVB\/N mice produces marked changes in lipid and glycemic metabolism","volume":"57","author":"Santos","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2014.10.005_bib0330","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.regpep.2012.06.009","article-title":"Increased circulating angiotensin-(1-7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet","volume":"178","author":"Santos","year":"2012","journal-title":"Regul Pept"},{"key":"10.1016\/j.peptides.2014.10.005_bib0335","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.peptides.2014.07.002","article-title":"Angiotensin 1-7: a peptide for preventing and treating metabolic syndrome","volume":"59C","author":"Santos","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2014.10.005_bib0340","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.peptides.2014.10.005_bib0345","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1872-034X.2011.00822.x","article-title":"Toll-like receptor signaling in liver regeneration, fibrosis and carcinogenesis","volume":"41","author":"Seki","year":"2011","journal-title":"Hepatol Res"},{"key":"10.1016\/j.peptides.2014.10.005_bib0350","doi-asserted-by":"crossref","first-page":"R1323","DOI":"10.1152\/ajpregu.00249.2013","article-title":"Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice","volume":"305","author":"Silva","year":"2013","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0355","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/138955706776876203","article-title":"The therapeutic potential of angiotensin-(1-7) as a novel renin-angiotensin system mediator","volume":"6","author":"Simoes e Silva","year":"2006","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.peptides.2014.10.005_bib0360","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10735-012-9441-z","article-title":"Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: stereology, histopathology, and electron microscopy","volume":"43","author":"Sipal","year":"2012","journal-title":"J Mol Histol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0365","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12072-010-9219-x","article-title":"The role of lipopolysaccharide\/toll-like receptor 4 signaling in chronic liver diseases","volume":"4","author":"Soares","year":"2010","journal-title":"Hepatol Int"},{"key":"10.1016\/j.peptides.2014.10.005_bib0370","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/01.qco.0000191509.56104.ec","article-title":"New paradigms in the management of HIV and hepatitis C virus coinfection","volume":"18","author":"Soriano","year":"2005","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.peptides.2014.10.005_bib0375","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/01.HYP.0000090322.55782.30","article-title":"Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7)","volume":"42","author":"Tallant","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.peptides.2014.10.005_bib0380","doi-asserted-by":"crossref","first-page":"H1560","DOI":"10.1152\/ajpheart.00941.2004","article-title":"Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor","volume":"289","author":"Tallant","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0385","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/jhep.2002.32679","article-title":"Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C","volume":"36","author":"Terui","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.peptides.2014.10.005_bib0395","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","article-title":"Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis","volume":"22","author":"Thein","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.peptides.2014.10.005_bib0400","doi-asserted-by":"crossref","first-page":"946","DOI":"10.7326\/0003-4819-141-12-200412210-00011","article-title":"Narrative review: hepatobiliary disease in type 2 diabetes mellitus","volume":"141","author":"Tolman","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.peptides.2014.10.005_bib0405","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cca.2005.06.014","article-title":"Mechanisms of liver fibrosis","volume":"364","author":"Tsukada","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.peptides.2014.10.005_bib0410","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10620-007-9941-y","article-title":"Effect of angiotensin-converting enzyme inhibition on experimental hepatic fibrogenesis","volume":"53","author":"Turkay","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.peptides.2014.10.005_bib0415","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s00535-006-1891-1","article-title":"Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats","volume":"41","author":"Ueki","year":"2006","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0420","first-page":"1100","article-title":"Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: a prospective study","volume":"56","author":"Ueki","year":"2009","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.peptides.2014.10.005_bib0425","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase","volume":"277","author":"Vickers","year":"2002","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.peptides.2014.10.005_bib0430","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/01.mnh.0000441052.44406.92","article-title":"Alamandine: a new member of the angiotensin family","volume":"23","author":"Villela","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.peptides.2014.10.005_bib0440","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1042\/CS20070026","article-title":"Liver fibrosis: a balance of ACEs?","volume":"113","author":"Warner","year":"2007","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.peptides.2014.10.005_bib0445","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.peptides.2014.10.005_bib0450","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3748\/wjg.v6.i6.824","article-title":"Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4)","volume":"6","author":"Wei","year":"2000","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0460","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/aps.2012.115","article-title":"Telmisartan attenuates hepatic fibrosis in bile duct-ligated rats","volume":"33","author":"Yi","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.peptides.2014.10.005_bib0465","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3748\/wjg.v12.i2.322","article-title":"Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis","volume":"12","author":"Yokohama","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.peptides.2014.10.005_bib0470","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/hep.20420","article-title":"Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis","volume":"40","author":"Yokohama","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.peptides.2014.10.005_bib0475","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1756-0500-2-70","article-title":"Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat","volume":"2","author":"Yoshiji","year":"2009","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.peptides.2014.10.005_bib0480","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/jhep.2001.28231","article-title":"Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats","volume":"34","author":"Yoshiji","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.peptides.2014.10.005_bib0485","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.rvsc.2013.01.028","article-title":"Up-regulation of components of the renin-angiotensin system in liver fibrosis in the rat induced by CCL(4)","volume":"95","author":"Zhang","year":"2013","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.peptides.2014.10.005_bib0220","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1053\/jhep.2003.50193","article-title":"Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference","volume":"37","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.peptides.2014.10.005_bib0455","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jhep.2005.02.034","article-title":"Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice","volume":"43","author":"Yang","year":"2005","journal-title":"J Hepatol"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978114003118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978114003118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T06:26:02Z","timestamp":1565936762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978114003118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":95,"alternative-id":["S0196978114003118"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2014.10.005","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of renin-angiotensin system modulation on treatment and prevention of liver diseases","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2014.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}